Abstract
A receptor can be activated either by specific ligand-directed changes in conformation or by intrinsic, spontaneous conformational change. In the β2-adrenergic receptor (AR) overexpression transgenic (TG4) murine heart, spontaneously activated β2AR (β2-R*) in the absence of ligands has been evidenced by elevated basal adenylyl cyclase activity and cardiac function. In the present study, we determined whether the signaling mediated by β2-R* differs from that of a ligand-elicited β2AR activation (β2-LR*). In ventricular myocytes from TG4 mice, the properties of L-type Ca2+ current (ICa), a major effector of β2-LR* signaling, was unaltered, despite a 2.5-fold increase in the basal cAMP level and a 1.9-fold increase in baseline contraction amplitude as compared with that of wild-type (WT) cells. Although the contractile response to β2-R* in TG4 cells was abolished by a β2AR inverse agonist, ICI118,551 (5 × 10−7 M), or an inhibitory cAMP analog, Rp-CPT-cAMPS (10−4 M), no change was detected in the simultaneously recorded ICa. These results suggest that the increase in basal cAMP due to β2-R*, while increasing contraction amplitude, does not affect ICa characteristics. In contrast, the β2AR agonist, zinterol elicited a substantial augmentation of ICa in both TG4 and WT cells (pertussis toxin-treated), indicating that L-type Ca2+channel in these cells can respond to ligand-directed signaling. Furthermore, forskolin, an adenylyl cyclase activator, elicited similar dose-dependent increase in ICa amplitude in WT and TG4 cells, suggesting that the sensitivity of L-type Ca2+channel to cAMP-dependent modulation remains intact in TG4 cells. Thus, we conclude that β2-R* bypasses ICa to modulate contraction, and that β2-LR* and β2-R* exhibit different intracellular signaling and target protein specificity.
Footnotes
- Received March 1, 1999.
- Accepted May 14, 1999.
-
Send reprint requests to: Rui-Ping Xiao, M.D., Ph.D., Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Dr., Baltimore, MD 21224. E-mail:xiaor{at}grc.nia.nih.gov
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|